Update shared on10 Aug 2025
Fair value Increased 11%Viemed Healthcare’s consensus price target has increased to $13.00, reflecting improvements in profitability and valuation as evidenced by a higher net profit margin and a lower future P/E.
What's in the News
- Raised 2025 net revenue guidance to $271–$277 million, up from $256–$265 million, driven by inclusion of Lehan's anticipated results.
- Removed from the Russell 2000 Dynamic Index.
- Announced a share repurchase program for up to 1,976,441 common shares (5% of issued capital), with purchases to be cancelled, valid through June 2026.
- Board authorized the share buyback plan.
- Held a special/extraordinary shareholders meeting at company headquarters in Lafayette, Louisiana.
Valuation Changes
Summary of Valuation Changes for Viemed Healthcare
- The Consensus Analyst Price Target has significantly risen from $11.75 to $13.00.
- The Future P/E for Viemed Healthcare has fallen from 23.41x to 21.88x.
- The Net Profit Margin for Viemed Healthcare has risen from 7.59% to 7.97%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.